RE:RE:Just scooped up some shares this morningPart of it is just the nature of pharma stocks and the development cycle. Without news all stocks drift downward and pharma stocks have built-in long stretches without news during clinical trials which leads to stagnation and a slowly depleted share price.
Mix in the day flippers, a few people cashing out to pursue other opportunities during the "clinical lull" and the occasional financial emergency leading some poor shmoe to liquidate his position overnight and there goes the bottom.
The company does try to fill the gap between clinical results with substance: presentations, conferences, CEO updates, Citagenix news, etc., but at best, I'd say these types of NRs only slow the descent while we continue to wait for the big news.
Barring excellent news in the interim, like a new Citagenix deal, financials showing a large increase in Citagenix revenue, initiation of ATB-352 human trials, etc... I see the slide continuing into Q4 then the SP beginning to trend higher end-of-year in anticipation of positive ATB-346 dose ranging results in Jan. 2019.
Just my thoughts...
WLE
Jefferam1 wrote: I humbly disagree...
First off I think ATE is crazy undervalued - Price should be much higher.
However between now and Q1 2019 when we get results from next trial, I believe there will be some dips and its very possible to see this price again.
That is the nature of the game, this is a penny stock and undervalued.
I hope we never see this price again but I would not bet on that until end of year.
Come January 1, 2019, then I would agree we will never see a sub 0.40 price again.
I'm hoping by then I'll be saying we will never see a sub 1.00 price again.